 Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Companys First-in-Class, Phase 11b Bi-steric mTORC1-Selective Inhibitor Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Companys First-in-Class, Phase 11b Bi-steric mTORC1-Selective Inhibitor 